3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
17
Thoracic
6
Head & Neck
5
Gastrointestinal
5
Breast
5
Gynecologic
4
Lymphoid
3
Genitourinary
3
CNS
3
Sarcoma
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myelodysplastic Syndromes
4
Myeloproliferative Disorders
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Waldenstrom Macroglobulinemia
2
Thrombocythemia, Essential
2
Primary Myelofibrosis
2
Polycythemia Vera
2
Neoplasms
2
Myelodysplastic-Myeloproliferative Diseases
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia
2
Congenital Abnormalities
2
Blast Crisis
2
Anemia, Refractory, with Excess of Blasts
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Interventions
tipifarnib
1
ruxolitinib
1
ripretinib
1
peginterferon alfa-2a
1
cobimetinib
1
cc-486
1
bemcentinib
1
avelumab
1
Vemurafenib
1
Standard of Care
1
Quality of Life
1
Practice Guidelines as Topic
1
Pentetic Acid
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Palliative Care
1
PLX8394
1
Nurse Clinicians
1
Molecular Diagnostic Techniques
1
Minocycline
1
Ipilimumab
1
Interferon alpha-2
1
Injections
1
In Situ Hybridization, Fluorescence
1
Immunotherapy
1
Imatinib Mesylate
1
Heparin
1
Fentanyl
1
Drug Therapy
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Drug Therapy
×
Myeloid
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled